Literature DB >> 3956561

Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.

H Spahn, W Kirch, P Hajdu, E Mutschler, E E Ohnhaus.   

Abstract

A possible interaction of penbutolol and cimetidine was investigated in healthy volunteers treated orally for 7 days. The plasma levels of unmetabolized penbutolol showed a slight but non-significant increase. The biphasic elimination kinetics of penbutolol (half-lives 0.8 and 17 h) was not affected by coadministration of cimetidine. Plasma levels of penbutolol were not significantly altered by chronic treatment with cimetidine, whereas the levels of 4-hydroxypenbutolol and 4-hydroxypenbutolol glucuronide were significantly reduced.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3956561     DOI： 10.1007/bf00635892

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  9 in total

1.  Plasma level studies of penbutolol after oral dose in man.

Authors:  J J Vallner; H W Jun; T E Needham; J T Stewart; W Brown; H Frazer; I L Honigberg
Journal:  J Clin Pharmacol       Date:  1977-04       Impact factor: 3.126

2.  Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Authors:  U Klotz; I W Reimann
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

Review 3.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  Determination of penbutolol and its hydroxylated metabolite in biological fluids by reversed-phase high-performance liquid chromatography.

Authors:  N Bernard; G Cuisinaud; J Sassard
Journal:  J Chromatogr       Date:  1982-03-12

5.  Plasma level profiles and clinical response of penbutolol after three different single oral doses in man.

Authors:  H W Jun; S L Hayes; J J Vallner; I L Honigberg; A E Rojos; J T Stewart
Journal:  J Clin Pharmacol       Date:  1979 Aug-Sep       Impact factor: 3.126

6.  Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man.

Authors:  A Wellstein; D Palm
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Pharmacodynamic and pharmacokinetic study of oral and intravenous penbutolol.

Authors:  J A Vedin; C Wilhelmsson; L Maass; L E Peterson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Physico-chemical and anlytical studies of penbutolol.

Authors:  P Hajdú; D Damm
Journal:  Arzneimittelforschung       Date:  1979

9.  Single and divided doses of penbutolol.

Authors:  F O Müller; H K Hundt; P A Bromley; J Torres; O Vanderbeke
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875
  9 in total
  4 in total

1.  Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.

Authors:  D Brockmeier; P Hajdù; W Henke; E Mutschler; D Palm; W Rupp; H Spahn; M T Verho; A Wellstein
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man.

Authors:  A Wellstein; D Palm
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.

Authors:  Aikaterini Zisaki; Ljubisa Miskovic; Vassily Hatzimanikatis
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

4.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.